Retail News Breaks Archives
NASP project to develop specialty Rx practice parameters
September 27th, 2013
ALEXANDRIA, Va. – The National Association of Specialty Pharmacy (NASP) has launched a national collaborative project to devise pharmacy practice parameters in about 20 specialty pharmacy therapeutic categories focused on disease management.
NASP said Thursday that each disease category has specific requirements allowing for the proper intake, clinical management, fulfillment and outcomes, and this full spectrum of responsible care — based on peer-reviewed and accepted standards — fosters improved patient outcomes and appropriate evidence for manufacturers, payers and providers.
The association reported that it expects the health care community to incorporate the parameters into patient registries that will be used across the industry, setting benchmarks to maintain access to product and payment information as the industry evolves.
"Our goal as an organization is to establish practice parameters that encompass clinical guidelines, existing standards and measures, benefit design, as well as management and information technology to measure adherence and outcomes," NASP chief executive officer Gary Cohen said in a statement. "We will collaborate with other stakeholders to utilize existing and emerging guidelines and adapt them to the specific needs of the specialty pharmacy community.
"Specialty pharmacists are playing a more integral role in the collaborative care model and will be a key driver of successful patient outcomes," Cohen added. "It is important that we develop practices parameters through consensus panels with key opinion leaders and subject matter experts."
NASP said it will incorporate the learnings of organizations into the final parameters, including URAC accreditation standards and the Pharmacy Quality Alliance (PQA) specialty pharmacy measures under development.
In addition, NASP plans to engage a variety of audiences including specialty pharmacists, pharmaceutical manufacturers, specialty pharmacy executives, payers, reimbursement consultants, disease-specific organizations and patient advocacy groups to complete the project. The parameters will also include information technology, adherence and outcomes metrics, enabling organizations to use and enhance a set of baseline standards.
"All the newly approved specialty pharmaceuticals targeted therapies coming on the market today require highly skilled specialized pharmacists who have disease- and drug-specific training and IT systems to support ongoing concurrent medication treatment management," explained Burt Zweigenhaft, chief executive officer of Onco360 and a NASP board member. "NASP is dedicated to providing and driving the health care market leadership and standards to ensure we as an industry deliver the promise of improved clinical utility and quality outcomes."
NASP said it's recruiting volunteers to work on advisory and consensus groups in different disease categories to support the development of practice parameters.